Subject
Neurology (clinical),Geriatrics and Gerontology,Neurology
Reference20 articles.
1. Considerations for development of an evidence dossier to support the use of mobile sensor technology for clinical outcome assessments in clinical trials, Contemp;Walton;Clin. Trials,2020
2. Digital progression biomarkers as novel endpoints in clinical trials: a multistakeholder perspective;Stephenson;J. Parkinsons Dis.,2021
3. Safety and efficacy of mevidalen in Lewy Body Dementia: a phase 2, randomized, placebo-controlled trial;Biglan;Mov. Disord.,2022
4. Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor
5. Safety, tolerability, and pharmacokinetics of mevidalen (LY3154207), a centrally acting dopamine D1 receptor, positive allosteric modulator (D1PAM), in healthy subjects;Wilbraham;Clin. Pharmacol. Drug Dev.,2021
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献